Graphite Bio Inc Stock
Graphite Bio Inc Stock price
Key metrics
| Market capitalization | $913.03m |
| Enterprise Value | $697.39m |
| P/E (TTM) P/E ratio | negative |
| P/B ratio (TTM) P/B ratio | 4.24 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-57.99m |
| Cash position | $217.22m |
| EPS (TTM) EPS | $-7.07 |
| P/E forward | negative |
Is Graphite Bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
Graphite Bio Inc Stock Analysis
Analyst Opinions
7 Analysts have issued a Graphite Bio Inc forecast:
Analyst Opinions
7 Analysts have issued a Graphite Bio Inc forecast:
Financial data from Graphite Bio Inc
| Sep '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -0.18 -0.18 |
98%
98%
|
|
| EBITDA | -58 -58 |
26%
26%
|
EBIT (Operating Income) EBIT | -58 -58 |
32%
32%
|
| Net Profit | -60 -60 |
52%
52%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Graphite Bio Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Graphite Bio, Inc. operates as a clinical-stage gene editing company. It focuses on therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo in June 2017 and is headquartered in South San Francisco, CA.
| Head office | United States |
| CEO | Evert Schimmelpennink |
| Employees | 6 |
| Founded | 2017 |
| Website | www.lenz-tx.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
